Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (13)

2023

  1. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 26, pp. 246-264

  2. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

2021

  1. Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

    Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820

  2. Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma

    Molecular Therapy - Oncolytics, Vol. 20, pp. 23-33

2020

  1. Sarcoma treatment in the era of molecular medicine

    EMBO Molecular Medicine, Vol. 12, Núm. 11

2019

  1. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [ 18 F]FDG and sodium [ 18 F]fluoride PET

    BMC Cancer, Vol. 18, Núm. 1

2016

  1. Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis

    Journal of Pathology, Vol. 239, Núm. 4, pp. 438-449

2014

  1. The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity

    Journal of Bone and Mineral Research, Vol. 29, Núm. 10, pp. 2287-2296

2009

  1. Molecular biology of pediatric bone sarcomas

    Pediatric Bone Sarcomas: Epiphysiolysis Before Excision (Springer London), pp. 19-32

  2. Proteomic analysis of chemonaïve pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets

    Journal of Proteome Research, Vol. 8, Núm. 8, pp. 3882-3888

2006

  1. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia

    Oncogene, Vol. 25, Núm. 13, pp. 1862-1870